The addition of cetuximab to platinum-based chemotherapy (cisplatin or carboplatin plus 5-
fluorouracil [5-FU]), followed by maintenance cetuximab until disease progression …

Background The combination platinum, 5-fluorouracil (5-FU) and cetuximab is the standard
first-line regimen of recurrent and/or metastatic head and neck squamous cell carcinoma …

Purpose: Treatment with cisplatin or cetuximab combined with radiotherapy each yield
superior survival in locally advanced squamous cell head and neck cancer (LA-SCCHN) …

Purpose Despite treatment, prognosis of unresectable squamous cell carcinoma of the head
and neck (SCCHC) is dismal. Cetuximab therapy has proven to increase the clinical activity …

This article summarizes the systemic treatment options for patients with recurrent and/or
metastatic squamous cell carcinoma of the head and neck, with an emphasis on …

Purpose This multicenter phase II study was undertaken to define the efficacy and safety of
cetuximab, an antiepidermal growth factor receptor chimeric human and murine monoclonal …

6012 Background: Cetuximab and paclitaxel have shown to be active in SCCHN pts and
preclinical data has demonstrated a possible synergy for the combination. In a variety of …

Background Recurrent/metastatic squamous cell carcinoma of head and neck (R/M SCCNH)
is still a difficult-to-treat disease with poor clinical outcomes and limited treatment choices. In …

Purpose: Locally recurrent head and neck squamous cell carcinoma can be treated with
curative intent by surgical salvage or reirradiation with or without chemotherapy. We have …

Background In patients with recurrent or metastatic head and neck squamous cell carcinoma
(R/M HNSCC) the estimated prognosis is usually poor. Patient-specific factors that affect …